Re: Men Need Fair Information About Screening for Prostate Cancer

Why It Matters

Misunderstanding the NND inflates perceived benefits of PSA screening, potentially shaping public opinion and national guidelines based on inaccurate risk‑benefit assessments.

Key Takeaways

• European trial: 1 prostate cancer death prevented per 456 screened men
• Number needed to diagnose is 12 excess cancers per death averted
• Overdiagnosis accounts for roughly 12 of 62 cancers diagnosed per death prevented
• Media often misread NND as 1‑in‑12 benefit, misleading patients
• Clear communication needed for informed consent and UK screening policy

Pulse Analysis

Prostate‑specific antigen (PSA) testing has long been a flashpoint in preventive health, with advocates citing mortality reductions while critics warn of unnecessary treatment. The 23‑year follow‑up of the European Randomized Study of Screening for Prostate Cancer provides the most robust evidence to date, confirming that inviting 456 men to screening saves a single prostate cancer death. However, the headline figure masks a more nuanced reality: for each death averted, about 62 men receive a cancer diagnosis, and 12 of those represent overdiagnosed cases that would never have surfaced without screening. This distinction is critical for clinicians who must weigh the modest survival benefit against the psychological and physical harms of overtreatment.

The concept of number needed to diagnose (NND) is central to interpreting these results, yet it is frequently conflated with the more familiar number needed to treat (NNT). NND quantifies the excess diagnoses required to prevent one death, effectively measuring the screening‑induced burden of overdiagnosis. In the European trial, the NND of 12 means that twelve additional men are labeled with prostate cancer solely because of the screening process, without any corresponding survival advantage. Media outlets that report the statistic as "1 in 12 men benefit" inadvertently present a misleading narrative that overstates the value of PSA testing and downplays its risks.

Accurate framing of these data has direct implications for policy and patient decision‑making. The UK National Screening Committee is currently reviewing recommendations, and clear communication about the true trade‑offs is essential for informed consent. Health journalists, medical societies, and clinicians should emphasize that while PSA screening can prevent deaths, it also leads to a substantial number of unnecessary diagnoses. By presenting both the mortality benefit and the overdiagnosis burden transparently, stakeholders can foster a more balanced public discourse and guide evidence‑based screening guidelines.